TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT01323257
First received: March 10, 2011
Last updated: October 10, 2012
Last verified: October 2012
  Purpose

The purpose of this study is to investigate the effect of steady-state concentrations of erythromycin or DRV/r on the steady-state pharmacokinetics of TMC435, the effect of a steady-state concentration of TMC435 (150 mg) on the steady-state pharmacokinetics of erythromycin and the effect of a steady-state concentration of TMC435 (50 mg) on the steady-state pharmacokinetics of DRV/r. We will also study the short-term safety and tolerability of TMC435 given alone and given togehter with erythromycin (Panel 1) or DRV/r (Panel 2). Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.


Condition Intervention Phase
Hepatitis C Virus
Drug: erythromycin
Drug: Ritonavir
Drug: TMC435
Drug: Darunavir
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r)

Resource links provided by NLM:


Further study details as provided by Tibotec Pharmaceuticals, Ireland:

Primary Outcome Measures:
  • Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with erythromycin (Panel 1). [ Time Frame: Measured on Day 1 and Day 5-10 (Trt C). Reference for TMC435 is on Day 1 and Day 5-10 of Trt A. ] [ Designated as safety issue: No ]
  • Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with DRV/r (Panel 2). [ Time Frame: Measured on Day 1 and Day 5-10 (Trt F). Reference for TMC435 is on Day 1 and Day 5-10 of Trt D. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in the steady-state plasma pharmacokinetics of erythromycin following co-administration with TMC435 (Panel 1). [ Time Frame: Measured on Day 1 and Day 5-7 (Trt C). Reference for erythromycin is on Day 1 and Day 5-7 of Trt B. ] [ Designated as safety issue: No ]
  • Change in the steady-state plasma pharmacokinetics of DRV/r following co-administration with TMC435 (Panel 2). [ Time Frame: Measured on Day 1 and Day 5-8 (Trt F). Reference for DRV/r is on Day 1 and Day 5-8 of Trt E. ] [ Designated as safety issue: No ]
  • Number of participants with adverse events as a measure of safety and tolerability - TMC435 and erythromycin [ Time Frame: Up to Day 67 ] [ Designated as safety issue: No ]
  • Number of participants with adverse events as a measure of safety and tolerability - TMC435 and DRV/r [ Time Frame: Up to Day 61 ] [ Designated as safety issue: No ]

Enrollment: 49
Study Start Date: March 2011
Study Completion Date: August 2011
Arms Assigned Interventions
Experimental: 001
TMC435 150 mg capsule once daily for 7 days (Trt A C D)
Drug: TMC435
150 mg capsule once daily for 7 days (Trt A, C, D)
Experimental: 002
erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
Drug: erythromycin
500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
Experimental: 003
erythromycin 500 mg tablets three times a day for 7 days (Trt C)
Drug: erythromycin
500 mg tablets three times a day for 7 days (Trt C)
Experimental: 004
TMC435 50 mg capsule once daily for 7 days (Trt F)
Drug: TMC435
50 mg capsule once daily for 7 days (Trt F)
Experimental: 005
Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
Drug: Darunavir
2 x 400 mg tablet once daily for 7 days (Trt E, F)
Experimental: 006
Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
Drug: Ritonavir
100 mg tablet once daily for 7 days (Trt E, F)

Detailed Description:

TMC435 is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). Erythromycin is an antibiotic and Darunavir/ritonavir (DRV/r) is currently indicated for the treatment of HIV infection. TMC435 is metabolized by the degradation enzyme CYP3A. Erythromycin and DRV/r are respectively moderate and strong inhibitors of the degradation enzyme CYP3A. The result of this study will provide dosing recommendations for TMC435 and for erythromycin or DRV/r, when being coadministered. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 48 healthy volunteers to investigate the pharmacokinetic interaction between TMC435, at steady state, and DRV/r or erythromycin, at steady-state. The volunteers will be allocated to one of two panels. In Panel 1, volunteers will receive three treatments (Trts A, B and C) in a randomized order. Volunteers will receive TMC435 150 mg once daily for 7 days (Trt A) and erythromycin 500 mg three times daily for 6 days + a morning dose on day 7 (Trt B) and TMC435 150 mg once daily for 7 days + erythromycin 500 mg three tmes daily for 7 days (Trt C). In Panel 2, volunteers will receive three treatments (Trts D, E and F) in a randomized order. Volunteers will receive TMC435 150 mg once daily for 7 days (Trt D), DRV/r 800/100 mg once daily for 7 days (Trt E) and TMC435 50 mg once daily for 7 days + DRV/r 800/100 mg once daly for 7 days (Trt F). In both panels, there will be a washout period (a period when no study drug will be taken, in order to have all the medication eliminated from the body before starting a new treatment) of at least 10 (Panel 1) or 7 (Panel 2) days between last intake of the study medication in one session and the first intake of study medication in the subsequent session. Pharmacokinetic profiles of all four compounds (TMC435, DRV, ritonavir and erythromycin) will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and during follow up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, on Day 1, Day 7 and Day 8 and at the follow up visit at 1 week after last dose of study medication in the last session. A physical examination will be performed at screening, on Day -1 (= day before first medication intake in each session for both panels) or Day 1, on Day 8 and during the follow-up visit. Volnteers will be admitted to the unit on Day-1, discharged on Day2, re-admitted on Day6 and discharged again on Day8. Each volunteer follows 3 treatment (Trt) periods, which are a minimum 10 days (Panel 1) or 7 days (Panel 2) apart from each other. All treatment periods take 7 days and all drugs are for oral intake. Panel 1: Trt A = 150 mg TMC435 once daily; Trt B = 500 mg erythromycin three times daily; Trt C: combining Trt A + B. Panel 2: Trt D = Trt A; Trt E = 800/100 mg DRV/r once daily; Trt D = 50 mg TMC435 once daily + Trt E.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non-smoker for at least 3 months
  • Body Mass Index of 18.0 to 30.0 kg/m2
  • Healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and electrocardiogram

Exclusion Criteria:

  • Infection with hepatitis A, B or C virus
  • Infection with the human immunodeficiency virus (HIV)
  • History of or any current medical condition which could impact the safety of the participant in the study
  • Having previously been dosed with TMC435 in a multiple-dose trial with TMC435
  • Having previously been dosed with TMC435 in more than 3 single-dose trials with TMC435
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01323257

Locations
Belgium
Antwerpen, Belgium
Sponsors and Collaborators
Tibotec Pharmaceuticals, Ireland
Investigators
Study Director: Tibotec Pharmaceuticals Clinical Trial Tibotec Pharmaceutical Limited
  More Information

No publications provided

Responsible Party: Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier: NCT01323257     History of Changes
Other Study ID Numbers: CR018010, TMC435-TiDP16-C115
Study First Received: March 10, 2011
Last Updated: October 10, 2012
Health Authority: Ireland: Irish Agriculture and Food Development Authority

Keywords provided by Tibotec Pharmaceuticals, Ireland:
TMC435-TiDP16-C115
TMC435-C115
TMC435
HCV
Hepatitis C
Hep C
healthy volunteers

Additional relevant MeSH terms:
Hepatitis
Hepatitis C
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases
Darunavir
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Ritonavir
Anti-Bacterial Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Gastrointestinal Agents
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Protein Synthesis Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014